News and Events

Algatech intends to launch several products using the algae-derived beta glucan, which will expand Algatech’s existing product offering and support its mission to develop commercial, microalgae-based products.

Algatech Ltd. has licensed the rights and intellectual property of technology belonging to F3 Platform Biologics that is designed to extract β-1,3-glucans from Euglena gracilis microalgae.

Fermentation expert Dr. Brad Cox, who has been instrumental in developing F3’s cutting-edge capabilities, will lead the Euglena project at Algatech and support its fermentation activity.

Microalgae-derived ingredient specialists Algatech are to license the rights to the production of β-1,3-glucan from microalgae Euglena gracilis from US biotech firm F3 Platform Biologics.

  The move seeks to bring better quality ß-1,3-glucans-based products to market 08 Aug 2019 --- Microalgae-derived ingredients player Algatech has licensed the rights and intellectual property related to the production of β-1,3-glucan from Euglena Gracilis

Paris, France — Solabia Group announced in a press release that it has acquired Algatech Ltd., which specializes in the development, cultivation and commercialization of ingredients delivered from microalgae for supplement, food and cosmetic brands.